drugset / Trial / NCT02149758

EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).

NCT02149758

Phase 4 Completed 40 enrolled Tatyasaheb Kore Dental College
RandomizedFactorialQuadruple-blindTreatment

Summary

The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by: 1. improving clinical periodontal parameters and, 2. improving the salivary SOD levels.

Timeline

Start
2013-01
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoricoxib Small molecule 60 mg

Indications